Clinical Trial Update: Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel and capecitabine for recurrent or metastatic head and neck squamous cell carcinoma was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of Nebraska | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-09-01